Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection

Blood

Volumn 98, Issue 6, 2001, Pages 1667-1677

  Lieberman, Judy ^a,b,c   Shankar, Premlata ^a,b   Manjunath, N ^a,b   Andersson, Jan ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; PERFORIN;

ANTIGEN PRESENTATION; ARTICLE; CELL MATURATION; CLONAL ANERGY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INTERFERON PRODUCTION; LYMPH NODE; MACROPHAGE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0035885920     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1667     Document Type: Article

References (182)

1. Reinhart TA, Rogan MJ, Viglianti GA, et al. A new approach to investigating the relationship between productive infection and cytopathicity in vivo. Nat Med. 1997;3:218-221.
2. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-989.
3. + T cells. Science. 1999;286:1353-1357.
4. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, et al. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol. 1989;142:452-462.
5. Moss PA, Rowland-Jones SL, Frodsham PM, et al. Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors. Proc Natl Acad Sci U S A. 1995;92:5773-5777.
6. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96.
7. + T cells in HIV-infected progressors and long-term nonprogressors. J Immunol. 2000;165:1082-1092.
8. Shankar P, Russo M, Harnisch B, et al. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood. 2000;96:3094-3101.
9. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science. 1986;234:1563-1566.
10. Walker BD, Chakrabarti S, Moss B, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987;328:345-348.
11. Plata F, Autran B, Martins LP, et al. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature. 1987;328:348-351.
12. + T cells. Science. 1995;270:1811-1815.
13. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature. 1995;378:563.
14. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650-4655.
15. Borrow P, Lewicki H, Wei X, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med. 1997;3:205-211.
16. Riviere Y, McChesney MB, Porrot F, et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retroviruses. 1995;11:903-907.
17. Kourtis AP, Ibegbu C, Nahmias AJ, et al. Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med. 1996;335:1431-1436.
18. + lymphocytes. Science. 1999;283:857-860.
19. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991-998.
20. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
21. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency type 1 infection. Nature. 1995;373:117-122.
22. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol. 1995;25:1071-1079.
23. Lieberman J. Cytotoxic T lymphocyte adoptive immunotherapy for HIV infection. In: Sitkovsky MV, Henkart PA, eds. Cytotoxic Cells: Basic Mechanisms and Medical Applications. Philadelphia, PA: Lippincott Williams & Wilkins; 1999, 441-457.
24. Koup RA, Sullivan JL, Levine PH, et al. Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood. 1989;73:1909-1914.
25. Riviere Y, Tanneau-Salvadori F, Regnault A, et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol. 1989;63:2270-2277.
26. Trimble LA, Lieberman J. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood. 1998;91:585-594.
27. + T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol. 1999;162:1780-1788.
28. + T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med. 2000;192:63-75.
29. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature. 1991;354:453-459.
30. Tsomides TJ, Alcovini A, Johnson RP, et al. Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med. 1994;180:1283-1293.
31. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol. 2000;18:861-926.
32. Jameson SC, Carbone FR, Bevan MJ. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med. 1993;177:1541-1550.
33. Kienerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature. 1994;369:403-407.
34. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 1991;252:1308-1310.
35. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 2000;407:386-390.
36. Schwartz O, Riviere Y, Heard JM, Danos O. Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol. 1993;67:3274-3280.
37. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility class I molecules is induced by the HIV-Nef protein. Nat Med. 1996;2:338-342.
38. Le Gall S, Heard JM, Schwartz O. Analysis of Nef-induced MHC-I endocytosis. Res Virol. 1997;148:43-47.
39. Greenberg ME, Iafrate AJ, Skowronski J. The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. EMBO J. 1998;17:2777-2789.
40. Collins KL, Chen BK, Kalarns SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998;391:397-401.
41. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A. 1997;94:1396-1401.
42. + T cells by a cytotoxic T-lymphocyte clone directed against a novel A2-restricted reverse-transcriptase epitope. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:111-120.
43. Shankar P, Xu Z, Lieberman J. Viral-specific cytotoxic T lymphocytes lyse HIV-infected primary T lymphocytes by the granule exocytosis pathway. Blood. 1999;94:3084-3093.
44. + T cells in the central region of the HIV-1 NEF protein. J Immunol. 1991;146:1560-1565.
45. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity. 1996;4:565-571.
46. Cohen GB, Gandhi RT, Davis DM, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity. 1999;10:661-671.
47. Maier CC, Greene MI. Biochemical features of anergic T cells. Immunol Res. 1998;17:133-140.
48. Clerici M, Stocks NI, Zajac RA, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature. 1989;339:383-385.
49. + long-term survivor. AIDS Res Hum Retroviruses. 1994;10:1703-1711.
50. Miedema F, Meyaard L, Koot M, et al. Changing virus-host interactions in the course of HIV-1 infection. Immunol Rev. 1994;140:35-72.
51. + T cell responses associated with control of viremia. Science. 1997;278:1447-1450.
52. Valentine FT, Paolino A, Saito A, Holzman RS. Lymphocyte-proliferative responses to HIV antigens as a potential measure of immunological reconstitution in HIV disease. AIDS Res Hum Retroviruses. 1998;14(suppl 2):S161-S166.
53. Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD. Characterization of HIV-1-specific T-helper cells in acute and chronic infection. Immunol Lett. 1999;66:89-93.
54. Lori F, Jessen H, Lieberman J, et al. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis. 1999;180:1827-1832.
55. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5:518-525.
56. + T cell proliferation and production of IFN-gamma in response to p24 antigen in HIV-infected individuals: potential contribution of anergy to HIV-specific unresponsiveness. J Immunol. 2000;165:1685-1691.
57. Chouaib S, Chehimi J, Bani L, et al. Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors. Proc Natl Acad Sci U S A. 1994;91:12659-12663.
58. Carini C, Essex M. Interleukin 2-independent interleukin 7 activity enhances cytotoxic immune response of HIV-1-infected individuals. AIDS Res Hum Retroviruses. 1994;10:121-130.
59. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 1998;8:615-623.
60. + T cells in vivo by IL-15. Immunity. 1998;8:591-599.
61. + memory T cells by opposing cytokines. Science. 2000;288:675-678.
62. Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001;7:73-79.
63. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signaling. Nature. 1998;393:478-480.
64. Borrow P, Tough DF, Eto D, et al. CD40 ligand-mediated interactions are involved in the generation of memory CD8(-) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection. J Virol. 1998;72:7440-7449.
65. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
66. + T cells. J Exp Med. 1996;184:863-871.
67. Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med. 1998;188:2205-2213.
68. Miedema F. Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. Immunodefic Rev. 1992;3:173-193.
69. + T cells from HIV-infected persons. J Immunol. 1994;153:412-420.
70. Macatonia SE, Patterson S, Knight SC. Suppression of immune responses by dendritic cells infected with HIV. Immunology. 1989;67:285-289.
71. Shearer GM. HIV-induced immunopathogenesis. Immunity. 1998;9:587-593.
72. + T cells. Immunol Rev. 1998;165:231-247.
73. Chen AI, McAdam AJ, Buhlmann JE, et al. Ox40-ligand has a critical costimulatory role in dendritic cell: T cell interactions. Immunity. 1999;11:689-698.
74. Gramaglia I, Cooper D, Miner KT, Kwon BS, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol. 2000;30:392-402.
75. Knight SC, Patterson S. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu Rev Immunol. 1997;15:593-615.
76. + T cells clonal expansion. Clin Exp Immunol. 1992;88:226-236.
77. + T lymphocytes in spleens of human immunodeficiency virus-positive patients. J Virol. 1995;69:4737-4745.
78. + T cells. J Immunol. 1995;155:4111-4117.
79. Ayehunie S, Garcia-Zepeda EA, Hoxie JA, et al. Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood. 1997;90:1379-1386.
80. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587-597.
81. Geijtenbeek TB, Torensma R, van Vliet SJ, et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell. 2000;100:575-585.
82. Blauvelt A, Chougnet C, Shearer GM, Katz SI. Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12. J Clin Invest. 1996;97:1550-1555.
83. Fan Z, Huang XL, Zheng L, et al. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. J Immunol. 1997;159:4973-4982.
84. Sapp M, Engelmayer J, Larsson M, et al. Dendritic cells generated from blood monocytes of HIV-1 patients are not infected and act as competent antigen presenting cells eliciting potent T-cell responses. Immunol Lett. 1999;66:121-128.
85. Canque B, Rosenzwajg M, Camus S, et al. The effect of in vitro human immunodeficiency virus infection on dendritic-cell differentiation and function. Blood. 1996;88:4215-4228.
86. + patients. AIDS Res Hum Retroviruses. 1998;14:505-513.
87. Chougnet C, Cohen SS, Kawamura T, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol. 1999;163:1666-1673.
88. Grassi F, Hosmalin A, McIlroy D, et al. Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS. 1999;13:759-766.
89. Clerici M, Landay AL, Kessler HA, et al. Multiple patterns of alloantigen presenting/stimulating cell dysfunction in patients with AIDS. J Immunol. 1991;146:2207-2213.
90. Dudhane A, Conti B, Orlikowsky T, et al. Monocytes in HIV type 1-infected individuals lose expression of costimulatory B7 molecules and acquire cytotoxic activity. AIDS Res Hum Retroviruses. 1996;12:885-892.
91. Orlikowsky T, Wang ZQ, Dudhane A, et al. The cell surface marker phenotype of macrophages from HIV-1-infected subjects reflects an IL-10 enriched and IFN-gamma-deprived donor environment. J Interferon Cytokine Res. 1996;16:957-962.
92. Badley AD, McElhinny JA, Leibson PJ, et al. Up-regulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol. 1996;70:199-206.
93. Orlikowsky T, Wang ZQ, Dudhane A, et al. Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion. AIDS Res Hum Retroviruses. 1997;13:953-960.
94. Dockrell DH, Badley AD, Villacian JS, et al. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest. 1998;101:2394-2405.
95. Caldwell RL, Egan BS, Shepherd VL. HIV-1 Tat represses transcription from the mannose receptor promoter. J Immunol. 2000;165:7035-7041.
96. Chougnet C, Wynn TA, Clerici M, et al. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus. J Infect Dis. 1996;174:46-53.
97. Chougnet C, Thomas E, Landay AL, et al. CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur J Immunol. 1998;28:646-656.
98. Ostrowski MA, Justement SJ, Ehler L, et al. The role of CD4(+) T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8(+) T cell responses. J Immunol. 2000;165:6133-6141.
99. Henkart PA. Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity. 1994;1:343-346.
100. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Immunol Rev. 1995;146:95-115.
101. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31-37.
102. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286:1957-1959.
103. Schijns VE, Wierda CM, van Hoeij M, Horzinek MC. Exacerbated viral hepatitis in IFN-gamma receptor-deficient mice is not suppressed by IL-12. J Immunol. 1996;157:815-821.
104. Geiger KD, Nash TC, Sawyer S, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology. 1997;238:189-197.
105. Bot A, Bot S, Bona CA. Protective role of gamma interferon during the recall response to influenza virus. J Virol. 1998;72:6637-6645.
106. Ogg GS, Jin X, Bonhoeffer S, et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998;279:2103-2106.
107. Chen G, Shankar P, Lange C, et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood. 2001;98:156-164.
108. + T cells. J Exp Med. 1997;186:1407-1418.
109. Roederer M, De Rosa S, Gerstein R, et al. 8 color, 10-parameter flow cytometry to elucidate complex leukocyte heterogeneity. Cytometry. 1997;29:328-339.
110. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
111. Trimble LA, Shankar P, Patterson M, Daily JP, Lieberman J. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol. 2000;74:7320-7330.
112. Garcia-Sanz JA, Velotti F, MacDonald HR, et al. Appearance of granule-associated molecules during activation of cytolytic T-lymphocyte precursors by defined stimuli. Immunology. 1988;64:129-134.
113. Andersson J, Behbahani H, Lieberman J, et al. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999;13:1295-1303.
114. + T-lymphocyte granules in lymphoid tissue during primary HIV-1 infection. J Infect Dis. In press.
115. Lieberman J, Fabry JA, Kuo MC, et al. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J Immunol. 1992;148:2738-2747.
116. Lieberman J, Fabry JA, Fong DM, Parkerson GR 3rd. Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses. 1997;13:383-392.
117. Betts MR, Casazza JP, Patterson BA, et al. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J Virol. 2000;74:9144-9151.
118. Altfeld MA, Livingston B, Reshamwala N, et al. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. J Virol. 2001;75:1301-1311.
119. Sercarz EE, Lehmann PV, Ametani A, et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol. 1993;11:729-766.
120. Leitenberg D, Bottomly K. Regulation of naive T cell differentiation by varying the potency of TCR signal transduction. Semin Immunol. 1999;11:283-292.
121. + cell suppression of HIV replication. J Immunol. 1997;159:5123-5131.
122. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature. 1998;391:908-911.
123. Patterson BK, Behbahani H, Kabat WJ, et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J Clin Invest. 2001;107:287-294.
124. Geiger KD, Nash TC, Sawyer S, et al. Interferon-gamma protects against herpes simplex virus type 1-mediated neuronal death. Virology. 1997;238:189-197.
125. Sarawar SR, Cardin RD, Brooks JW, et al. Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. J Virol. 1997;71:3916-3921.
126. Bot A, Bot S, Bona CA. Protective role of gamma interferon during the recall response to influenza virus. J Virol. 1998;72:6637-6645.
127. Ullum H, Cozzi Lepri A, Bendtzen K, et al. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses. 1997;13:1039-1046.
128. Bailer RT, Holloway A, Sun J, et al. IL-13 and IFN-gamma secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression. J Immunol. 1999;162:7534-7542.
129. Huang XL, Fan Z, Kalinyak C, Mellors JW, Rinaldo CR Jr. CD8(+) T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects. Clin Diagn Lab Immunol. 2000;7:279-287.
130. Goepfert PA, Bansal A, Edwards BH, et al. A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon. J Virol. 2000;74:10249-10255.
131. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity, 1998;8:177-187.
132. + T cells during an acute virus infection. Immunity. 1998;8:167-175.
133. Goulder PJ, Tang Y, Brander C, et al, Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med. 2000;192:1819-1832.
134. + T cells during the chronic phase of infection. J Virol, 2001;75:2458-2461.
135. Luscher U, Filgueira L, Juretic A, et al. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes. Int J Cancer, 1994;57:612-619.
136. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999;5:677-685.
137. + T cells specific for melanocyte differentiation antigens expresses killer inhibitory receptors (KIR) in healthy donors: evidence for a role of KIR in the control of peripheral tolerance. Eur J Immunol. 2000;30:1665-1675.
138. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell. 1994;76:263-274.
139. Dustin ML, Chan AC. Signaling takes shape in the immune system. Cell. 2000;103:283-294.
140. van der Merwe AP, Davis SJ, Shaw AS, Dustin ML. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin Immunol. 2000;12:5-21.
141. Rozdzial MM, Malissen B, Finkel TH. Tyrosinephosphorylated T cell receptor zeta chain associates with the actin cytoskeleton upon activation of mature T lymphocytes. Immunity. 1995;3:623-633.
142. Caplan S, Zeliger S, Wang L, Baniyash M. Cell-surface-expressed T-cell antigen-receptor zeta chain is associated with the cytoskeleton. Proc Natl Acad Sci U S A. 1995;92:4768-4772.
143. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16:201-223.
144. Geertsma MF, van Wengen-Stevenhagen A, van Dam EM, et al. Decreased expression of zeta molecules by T lymphocytes is correlated with disease progression in human immunodeficiency virus-infected persons. J Infect Dis. 1999;180:649-658.
145. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science. 1992;258:1795-1798.
146. Finke JH, Zea AH, Stanley J, et al. Loss of cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613-5616.
147. Massaia M, Attisano C, Beggiato E, Bianchi A, Piled A. Correlation between disease activity and T-cell CD3 zeta chain expression in a B-cell lymphoma. Br J Haematol. 1994;88:886-888.
148. Renner C, Ohnesorge S, Held G, et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood. 1996;88:236-241.
149. Stefanova I, Saville MW, Peters C, et al. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression. J Clin Invest. 1996;98:1290-1297.
150. Trimble LA, Kam LW, Friedman RS, Xu Z, Lieberman J. CD3zeta and CD28 down-modulation on CD8 T cells during viral infection. Blood. 2000;96:1021-1029.
151. Trimble LA. Down-modulation of CD3zeta, the signaling chain of the T cell receptor complex, is associated with CD8 T cell dysfunction in HIV infection [dissertation]. Boston, MA: Sackler School of Graduate Biomedical Sciences, Tufts University; 1998.
152. Helms T, Boehm BO, Asaad RJ, et al. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J Immunol. 2000;164:3723-3732.
153. + memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol. 1998;161:5284-5295.
154. Kovacs JA, Vogel S, Albert JM, et al. Controiled Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
155. Spiegel HM, Ogg GS, DeFalcon E, et al. Human immunodeficiency virus type 1- and cytomegalo-virus-specific cytotoxic T lymphocytes can persist at high frequency for prolonged periods in the absence of circulating peripheral CD4(+) T cells. J Virol, 2000;74:1018-1022.
156. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med, 1998;188:2199-2204.
157. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
158. Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr Opin Immunol. 2000;12:375-380.
159. De Maria A, Moretta L. HLA-class I-specific inhibitory receptors in HIV-1 infection. Hum Immunol. 2000;61:74-81.
160. Mingari MC, Ponte M, Vitale C, et al. Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes: functional relevance and implications for anti-tumor immune responses. Int J Clin Lab Res. 1997;27:87-94.
161. Vales-Gomez M, Reyburn H, Strominger J. Molecular analyses of the interactions between human NK receptors and their HLA ligands. Hum Immunol. 2000;61:28-38.
162. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum Immunol. 2000;61:44-50.
163. Galiani MD, Aguado E, Tarazona R, et al. Expression of killer inhibitory receptors on cytotoxic cells from HIV-1-infected individuals. Clin Exp Immunol. 1999;115:472-476.
164. + T-cell clones in HIV-1 infection. Immunol Lett. 2000;72:179-182.
165. De Maria A, Ferraris A, Guastella M, et al. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions. Proc Natl Acad Sci U S A. 1997;94:10285-10288.
166. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
167. Nakano H, Mori S, Yonekawa H, et al. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood. 1998;91:2886-2895.
168. Forster R, Schubel A, Breitfeld D, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999;99:23-33.
169. Stein JV, Rot A, Luo Y, et al. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J Exp Med. 2000;191:61-76.
170. Campbell JJ, Bowman EP, Murphy K, et al. 6-Ckine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol. 1998;141:1053-1059.
171. Tangemann K, Gunn MD, Giblin P, Rosen SD. A high endothelial cell-derived chemokine induces rapid, efficient, and subset-selective arrest of rolling T lymphocytes on a reconstituted endothelial substrate. J Immunol. 1998;161:6330-6337.
172. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med. 1990;171:801-817.
173. Vitetta ES, Berton MT, Burger C, et al. Memory B and T cells. Annu Rev
174. Gray D. Immunological memory. Annu Rev Immunol. 1993;11:49-77.
175. Swain SL, Croft M, Dubey C, et al. From naive to memory T cells. Immunol Rev. 1996;150:143-167.
176. Kuroda MJ, Schmitz JE, Charini WA, et al. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol. 1999;162:5127-5133.
177. Meylan PR, Burgisser P, Weyrich-Suter C, Spertini F. Viral load and immunophenotype of cells obtained from lymph nodes by fine needle aspiration as compared with peripheral blood cells in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:39-47.
178. Landay AL, Bethel J, Schnittman S. Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses. 1998;14:445-451.
179. + T cells. Clin Immunol Immunopathol. 1996;81:200-209.
180. Pantaleo G, Soudeyns H, Demarest JF, et al. Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection. Eur J Immunol. 1997;27:3166-3173.
181. Brodie SJ, Lewinsohn DA, Patterson BK, et al. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat Med. 1999;5:34-41.
182. Kalams SA, Buchbinder SP, Rosenberg ES, et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol. 1999;73:6715-6720.